# A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Study · id `cardio:ct-nct07564414` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07564414](<https://clinicaltrials.gov/study/NCT07564414>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07564414

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.

## Technical summary

Registry record NCT07564414. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-21 (actual); primary completion 2028-02-23 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2500 participants (planned count; ClinicalTrials.gov record NCT07564414, source copy `cardio:ctgov-nct07564414-2026-09-30`, retrieved 2026-10-26)
- Started: 2026-05-21 (actual) (ClinicalTrials.gov record NCT07564414, source copy `cardio:ctgov-nct07564414-2026-09-30`, retrieved 2026-10-26)
- Primary completion: 2028-02-23 (anticipated) (ClinicalTrials.gov record NCT07564414, source copy `cardio:ctgov-nct07564414-2026-09-30`, retrieved 2026-10-26)
- Completion: 2028-04-19 (anticipated) (ClinicalTrials.gov record NCT07564414, source copy `cardio:ctgov-nct07564414-2026-09-30`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Bulgaria; Canada; Czechia; France; Greece; Hungary; Italy; Netherlands; Poland; Portugal; Romania; Slovakia; South Africa; Spain (ClinicalTrials.gov record NCT07564414, source copy `cardio:ctgov-nct07564414-2026-09-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07564414-2026-09-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Condition: Obesity
- Condition: Type 2 Diabetes
- Intervention (Drug): Cagrisema
- Intervention (Drug): Semaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 7d7075abd9009fb3695002cd7be5808cb8a044113247752764edb90cbb23cf4d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
